Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250 and 500 mg in the European Union

20 juli 2009 MILAN, ITALY--(Marketwire - July 20, 2009) - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Decentralized Procedure (DCP) for registration of Paracetamol 250 and 500 mg Orodispersible Tablets (ODT) in several EU countries has been successfully completed. In addition to The Netherlands, which acted as the reference member state, the DCP involved the United Kingdom, Germany, France, Italy and Spain. Formal approval is now expected from each country by the end of 2009. Eurand is actively seeking a partner to market and distribute Paracetamol ODT in these countries. Paracetamol (also known as acetaminophen) is a widely used analgesic (pain reliever) and antipyretic (fever reducer). Paracetamol ODT is indicated for symptomatic treatment of mild-to-moderate pain and/or fever. The 500 mg dose is indicated in adults and adolescents (over 12 years old) only, and the 250 mg dose is for use in children from the age of four and adolescents only. The product may be taken with or without liquid. "We are pleased by the Dutch MEB's decision regarding our Paracetamol ODT, and we look forward to receiving approval in the six individual countries later this year," said Gearóid Faherty, Chairman and Chief Executive Officer. "We believe our formulation will deliver this well-recognized pain reliever in a more patient friendly manner, particularly for those patients who have difficulty swallowing." He noted that this is the second ODT formulation that Eurand has had approved this year. In May 2009, the FDA approved EUR-1048, marketed by GlaxoSmithKline as Lamictal® ODT(TM) (lamotrigine) Orally Disintegrating Tablets. Like Paracetamol ODT, Lamictal ODT uses Eurand's AdvaTab® orally disintegrating tablet (ODT) and Microcaps® taste-masking technologies. About Eurand Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had five products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at www.eurand.com. Forward-Looking Statement This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to the future and status of our regulatory filings, development plans and product development activities. The words "potentially," "anticipates," "could," "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that regulatory agencies do not approve the registration of Paracetamol ODT; unexpected delays or additional requirements. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements. LAMICTAL ODT is a trademark of the GlaxoSmithKline group of companies. Contacts: Bill Newbould Vice President, Investor Relations Eurand N.V. +1 267-759-9335 bill.newbould@eurand.com Nick Laudico/Sara Pellegrino The Ruth Group +1 646-536-7030/7002 nlaudico@theruthgroup.com spellegrino@theruthgroup.com This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.